No headlines found.
No press releases found.
No news found.
Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).
Niki Biosolutions trades on the NASDAQ stock market under the symbol NIKI.
As of July 22, 2026, NIKI stock price declined to $8.99 with 25,762 million shares trading.
NIKI has a market cap of $73.21 million. This is considered a Micro Cap stock.
NIKI support price is $7.32 and resistance is $11.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NIKI shares will trade within this expected range on the day.
